Android Apple

Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

By Yahoo! Finance   |   2 weeks ago
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

Merck's sacituzumab tirumotecan (sac-TMT) designated Breakthrough Therapy by FDA for advanced NSCLC with EGFR mutations. The novel drug combination targets TROP2, showing promise in treating various malignancies.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.